What is psoriasis?

Children and psoriasis

Scalp psoriasis

Psoriatic arthritis

Sensitive Areas

Guttate psoriasis

Pustular Psoriasis

Treatments

Frequently Asked Questions

Podcasts

How you can help

Research

Jargon buster

Journal

Links to other sites

 

 

 

 

Efalizumab - Raptiva

February 2009
The European Medicines Agency (EMEA) has recently reviewed Efalizumab (Raptiva) following concerns regarding the long-term safety for patients. The EMEA have recommended that the marketing authorisation should be withdrawn across Europe. Patients currently using Raptiva should make an appointment with their Dermatologist to discuss an alternative treatment, but should not stop Rapitva abruptly.
Patients who have taken Raptiva in the past and have any questions or concerns should make an appointment with their GP or Dermatologist.
For further information, please visit http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/RaptivaQ&A_1552509en.pdf


 
   
If this information has helped you, please help us by sending a donation
     
Registered charity 257414
Scottish Charity Number SC039866